UK ranks 22nd out of 29 comparable countries for survival of Brain Cancer
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
Read more
Experimental GBM treatment — DC Vax — is hoped to be moving forward in the UK
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
White House Cancer Moonshot
OurBrainBank is proud that the White House invited us to be part of the ambitious Cancer Moonshot effort. Read the latest from Washington DC.
OurBrainBank at SNO — Society for Neuro-Oncology — Annual Conference
Executive Director Kelli Duprey presented our poster about treatment disparities at SNO 2023